Showing posts with label NIH. Show all posts
Showing posts with label NIH. Show all posts

Wednesday, 5 May 2021

The origin of Covid: Did people or nature open Pandora’s box at Wuhan?

‘If the case that SARS2 originated in a lab is so substantial, why isn’t this more widely known? As may now be obvious, there are many people who have reason not to talk about it. The list is led, of course, by the Chinese authorities. But virologists in the United States and Europe have no great interest in igniting a public debate about the gain-of-function experiments that their community has been pursuing for years.

‘Nor have other scientists stepped forward to raise the issue. Government research funds are distributed on the advice of committees of scientific experts drawn from universities. Anyone who rocks the boat by raising awkward political issues runs the risk that their grant will not be renewed and their research career will be ended. Maybe good behavior is rewarded with the many perks that slosh around the distribution system. And if you thought that Andersen and Daszak might have blotted their reputation for scientific objectivity after their partisan attacks on the lab escape scenario, look at the second and third names on this list of recipients of an $82 million grant announced by the National Institute of Allergy and Infectious Diseases in August 2020.

‘The US government shares a strange common interest with the Chinese authorities: Neither is keen on drawing attention to the fact that Shi’s coronavirus work was funded by the US National Institutes of Health. One can imagine the behind-the-scenes conversation in which the Chinese government says, “If this research was so dangerous, why did you fund it, and on our territory too?” To which the US side might reply, “Looks like it was you who let it escape. But do we really need to have this discussion in public?”

‘Fauci is a longtime public servant who served with integrity under President Trump and has resumed leadership in the Biden Administration in handling the COVID-19 epidemic. Congress, no doubt understandably, may have little appetite for hauling him over the coals for the apparent lapse of judgment in funding gain-of-function research in Wuhan.

‘To these serried walls of silence must be added that of the mainstream media. To my knowledge, no major newspaper or television network has yet provided readers with an in-depth news story of the lab escape scenario, such as the one you have just read, although some have run brief editorials or opinion pieces. One might think that any plausible origin of a virus that has killed three million people would merit a serious investigation. Or that the wisdom of continuing gain-of-function research, regardless of the virus’s origin, would be worth some probing. Or that the funding of gain-of-function research by the NIH and NIAID during a moratorium on such research would bear investigation. What accounts for the media’s apparent lack of curiosity?

‘The virologists’ omertà is one reason. Science reporters, unlike political reporters, have little innate skepticism of their sources’ motives; most see their role largely as purveying the wisdom of scientists to the unwashed masses. So when their sources won’t help, these journalists are at a loss.

‘Another reason, perhaps, is the migration of much of the media toward the left of the political spectrum. Because President Trump said the virus had escaped from a Wuhan lab, editors gave the idea little credence. They joined the virologists in regarding lab escape as a dismissible conspiracy theory. During the Trump administration, they had no trouble in rejecting the position of the intelligence services that lab escape could not be ruled out. But when Avril Haines, President Biden’s director of national intelligence, said the same thing, she too was largely ignored. This is not to argue that editors should have endorsed the lab escape scenario, merely that they should have explored the possibility fully and fairly.

‘People round the world who have been pretty much confined to their homes for the last year might like a better answer than their media are giving them. Perhaps one will emerge in time. After all, the more months pass without the natural emergence theory gaining a shred of supporting evidence, the less plausible it may seem. Perhaps the international community of virologists will come to be seen as a false and self-interested guide. The common sense perception that a pandemic breaking out in Wuhan might have something to do with a Wuhan lab cooking up novel viruses of maximal danger in unsafe conditions could eventually displace the ideological insistence that whatever Trump said can’t be true.

‘And then let the reckoning begin.’

Read here (Bulletin of the Atomic Scientists, May 5, 2021)

Sunday, 18 April 2021

Large clinical trial to study repurposed drugs to treat Covid-19 symptoms

‘The National Institutes of Health will fund a large, randomized, placebo‑controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID‑19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership, the ACTIV-6 trial aims to provide evidence-based treatment options for the majority of adult patients with COVID-19 who have mild-to-moderate symptoms and are not sick enough to be hospitalized. NIH will provide an initial investment of $155 million in funding for the trial.

‘Several drugs currently are recommended for the treatment of hospitalized patients with moderate to severe COVID-19, including the antiviral drug remdesivir, the anti-inflammatory baricitinib, and corticosteroids. Additionally, the U.S. Food and Drug Administration authorized emergency use of intravenous monoclonal antibodies in non-hospitalized patients with mild to moderate COVID-19 who are at high risk for severe disease. However, medications that can be self-administered at home to reduce COVID-19 symptoms are critically needed.’

Read here (NIH, Apr 19, 2021)

Monday, 8 March 2021

Most Covid-19 hospitalisations due to four conditions

‘Based on this data, the model calculated the percentage of COVID-19 hospitalizations that could have been prevented without these four underlying conditions. Results were published in the Journal of the American Heart Association on February 25, 2021. The researchers estimated that more than 900,000 COVID-19 hospitalizations occurred through November 2020. Based on their model, 30% of these hospitalizations were attributable to obesity, 26% to hypertension, 21% to diabetes, and 12% to heart failure. These people would still have been infected with COVID-19, but likely would not have been sick enough to need hospitalization.

‘More than one of these conditions are often present in the same person. The model also estimated hospitalizations due to different combinations. The numbers weren’t simply additive. In total, 64% of the hospitalizations might have been prevented if not for the four conditions. The model suggested that COVID-19 hospitalizations due to these conditions varied by age. Older adults with diabetes, heart failure, or hypertension were more likely to be hospitalized than younger people with the same condition. However, obesity affected COVID-19 hospitalization risk similarly across age groups.’

Read here (NIH, Mar 9, 2021)

Tuesday, 2 March 2021

NIH halts trial of Covid-19 convalescent plasma in emergency department patients with mild symptoms: ‘Safe but no significant benefit’

‘The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in treating emergency department patients who developed mild to moderate symptoms of COVID-19, the disease caused by the coronavirus SARS-CoV-2.

‘An independent data and safety monitoring board (DSMB) met on Feb. 25, 2021 for the second planned interim analysis of the trial data and determined that while the convalescent plasma intervention caused no harm, it was unlikely to benefit this group of patients. After the meeting, the DSMB recommended that the National Heart, Lung, and Blood Institute (NHLBI), part of NIH, stop enrolling new patients into the study. NHLBI did so immediately.’

Read here (NIH, Mar 2, 2021) 

Monday, 22 February 2021

US National Institutes of Health launch new initiative to study “Long Covid”

Some of the initial underlying questions that this initiative hopes to answer are:

  • What does the spectrum of recovery from SARS-CoV-2 infection look like across the population?
  • How many people continue to have symptoms of COVID-19, or even develop new symptoms, after acute SARS-CoV-2 infection?
  • What is the underlying biological cause of these prolonged symptoms?
  • What makes some people vulnerable to this but not others?
  • Does SARS-CoV-2 infection trigger changes in the body that increase the risk of other conditions, such as chronic heart or brain disorders?

These initial research opportunities will support a combination of ongoing and new research studies and the creation of core resources. We anticipate subsequent calls for other kinds of research, in particular opportunities focused on clinical trials to test strategies for treating long-term symptoms and promoting recovery from infection.

Read here (NIH, Feb 23, 2021)

Friday, 15 January 2021

Association of American Physicians and Surgeons (AAPS) applauds NIH revised stance on Ivermectin for Covid-19

‘The National Institutes (NIH) has issued a new statement on the use of the anti-parasitic drug ivermectin for the treatment of COVID-19. Previously, it recommended against this treatment, but now states that its Panel “has determined that there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19.”

‘The Association of American Physicians and Surgeons (AAPS) notes that there are now 49 ivermectin studies summarized on c19study.com, 100 percent of which show favorable results. In contrast, there are very few studies of the antibody cocktails now being used under an Emergency Use Authorization.

‘NIH concludes from its current analysis that “results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance on the role of ivermectin in the treatment of COVID-19.” The NIH may be responding to requests related to the testimony strongly favoring ivermectin in a Dec 8 Senate hearing before the Committee on Homeland Security and Governmental Affairs.’

Read here (Globe Newswire, Jan 15, 2021)

Thursday, 14 January 2021

Ivermectin is now a therapeutic option for doctors & prescribers

‘One week after Dr. Paul Marik and Dr. Pierre Kory – founding members of the Front Line Covid-19 Critical Care Alliance (FLCCC) – along with Dr. Andrew Hill, researcher and consultant to the World Health Organization (WHO), presented their data before the NIH Treatment Guidelines Panel, the NIH has upgraded their recommen­da­tion and now considers Ivermectin an option for use in COVID-19.

‘Their recommendation has now been upgraded to the same level as those for widely used monoclonal antibodies & convalescent plasma, which is a “neither for nor against” recommen­da­tion. The significance of this change is that the NIH has decided to no longer recommend against the use of ivermectin in the treatment of COVID-19 by the nation’s health care providers. A consequence of this change is that ivermectin has now been made a clear therapeutic option for patients.’

Read here and press release here (FLCCC Alliance, Jan 15, 2021)

Friday, 4 December 2020

Covid survivors with long-term symptoms need urgent attention, experts say

‘There is an urgent need to address long-term symptoms of the coronavirus, leading public health officials said this week, warning that hundreds of thousands of Americans and millions of people worldwide might experience lingering problems that could impede their ability to work and function normally.

‘In a two-day meeting Thursday and Friday, the federal government’s first workshop dedicated to long-term Covid-19, public health officials, medical researchers and patients said the condition needed to be recognized as a syndrome, given a name and taken seriously by doctors. “This is a phenomenon that is really quite real and quite extensive,” Dr. Anthony S. Fauci, the nation’s top infectious diseases expert, said at the conference on Thursday.’

Read here (New York Times, Dec 4, 2020)

Monday, 14 September 2020

NIH ‘very concerned’ about serious side effect in coronavirus vaccine trial​

‘A great deal of uncertainty remains about what happened to the unnamed patient, to the frustration of those avidly following the progress of vaccine testing. AstraZeneca, which is running the global trial of the vaccine it produced with Oxford University, said the trial volunteer recovered from a severe inflammation of the spinal cord and is no longer hospitalized.

‘AstraZeneca has not confirmed that the patient was afflicted with transverse myelitis, but Nath and another neurologist said they understood this to be the case. Transverse myelitis produces a set of symptoms involving inflammation along the spinal cord that can cause pain, muscle weakness and paralysis. Britain’s regulatory body, the Medicines and Healthcare Products Regulatory Agency, reviewed the case and has allowed the trial to resume in the United Kingdom.’

Read here (Scientific American, Sept 15, 2020)

Saturday, 22 August 2020

The Covid-19 pandemic is fueling the opioid crisis

 This fact sheet provided by the US National Institute of Environmental Health Sciences:

  • Identifies the link between the COVID-19 pandemic and an increased risk of opioid misuse.
  • Provides tips to manage stressors caused by the pandemic.

Read here (NIH, undated circa 2020)

Thursday, 26 March 2020

Genomic study points to natural origin of COVID-19, says NIH Director’s blog. Two scenarios suggested

‘In the first scenario, as the new coronavirus evolved in its natural hosts, possibly bats or pangolins, its spike proteins mutated to bind to molecules similar in structure to the human ACE2 protein, thereby enabling it to infect human cells. This scenario seems to fit other recent outbreaks of coronavirus-caused disease in humans, such as SARS, which arose from cat-like civets; and Middle East respiratory syndrome (MERS), which arose from camels.

‘The second scenario is that the new coronavirus crossed from animals into humans before it became capable of causing human disease. Then, as a result of gradual evolutionary changes over years or perhaps decades, the virus eventually gained the ability to spread from human-to-human and cause serious, often life-threatening disease.

‘Either way, this study leaves little room to refute a natural origin for COVID-19. And that’s a good thing because it helps us keep focused on what really matters: observing good hygiene, practicing social distancing, and supporting the efforts of all the dedicated health-care professionals and researchers who are working so hard to address this major public health challenge.’

Read here (NIH Director’s Blog, March 26, 2020)

Read here too on ‘The proximal origin of SARS-CoV-2’ (Nature Medicine, March 17, 2020)

Friday, 31 December 2004

Case for wearing face masks (1): People who wore masks during the SARS outbreak had a 70% lower risk of being diagnosed compared with those who never wore masks

‘We also used this investigation to quantify the impact of behaviours (i.e. mask wearing, handwashing) that were promoted to reduce the risk for SARS. Wearing masks outside the home in a reference period corresponding to the 2 weeks before symptom onset for cases was significantly protective against clinical SARS.

‘Supporting the validity of this finding, there was a dose-response effect: by multivariable analysis, persons who always wore masks had a 70% lower risk of being diagnosed with clinical SARS compared with those who never wore masks, and persons with intermittent mask use had a 60% lower risk.’

Read here (NIH, 2004)

Worst ever Covid variant? Omicron

John Campbell shares his findings on Omicron.  View here (Youtube, Nov 27, 2021)